Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Trial: Engineered Donor Graft (Orca Q) for Pediatric Hematopoietic Cell Transplant (HCT) Recipients With Hematologic Malignancies (HM)

NCT05322850 is registered in ClinicalTrials.gov with University of Florida as lead sponsor.

NCT NCT05322850
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05322850 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Trial: Engineered Donor Graft (Orca Q) for Pediatric Hematopoietic Cell Transplant (HCT) Recipients With Hematologic Malignancies (HM)
Lead sponsor
University of Florida
Phase
Phase 1/2
Overall status
Recruiting
Start date
August 16, 2022
Completion date
September 30, 2027
Enrollment
40 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

acute lymphoid leukemia, acute myeloid leukemia, acute undifferentiated leukemia, chronic myeloid leukemia - accelerated phase, chronic myeloid leukemia in lymphoid blast crisis (diagnosis), chronic myeloid leukemia in myeloid blast crisis, mixed phenotype acute leukemia